In another type of ALS mouse, methylene blue didn’t help them move better or change any of the abnormal brain proteins or inflammation markers that are linked to the disease.
Scientific Claim
Methylene blue administration had no effect on motor function in TDP-43(G348C) transgenic mice, and did not alter cytosolic translocation of TDP-43, ubiquitination, or inflammation.
Original Statement
“In TDP-43(G348C) mice, MB failed to improve motor function. Cytosolic translocation of TDP-43, ubiquitination and inflammation remained also unchanged after MB treatment of TDP-43(G348C) mice.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract lacks details on experimental controls. 'Failed to improve' and 'remained unchanged' imply causation without confirmed methodology. Only neutral, descriptive language is justified.
More Accurate Statement
“In TDP-43(G348C) transgenic mice, methylene blue administration was not associated with improvements in motor function or changes in cytosolic translocation of TDP-43, ubiquitination, or inflammation.”
Evidence from Studies
Supporting (1)
Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models
The scientists gave methylene blue to mice with a form of ALS and found it didn’t help them move better or change the harmful protein buildup in their brains — so the drug didn’t do anything useful in this case.